Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Giovanni Cei"'
Autor:
Tiziana, Sampietro, Mariarita, Puntoni, Federico, Bigazzi, Benedetto, Pennato, Francesco, Sbrana, Beatrice, Dal Pino, Antonio, Azzarà, Enrico, Magagnini, Paolo, Perossini, Giovanni, Cei, Giovanni, Bacci
Publikováno v:
Circulation. 119(20)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b4bd85d8e55b823601b401e8859bd3e4
https://pubmed.ncbi.nlm.nih.gov/19470903
https://pubmed.ncbi.nlm.nih.gov/19470903
Autor:
Benedetto Pennato, Federico Bigazzi, Tiziana Sampietro, Paolo Perossini, Enrico Magagnini, Mariarita Puntoni, Antonio Azzarà, Beatrice Dal Pino, Francesco Sbrana, Giovanni Bacci, Giovanni Cei
Publikováno v:
Circulation. 119:2741-2742
A 37-year-old man was first referred to our lipid clinic in December 2007 for plasma lipid alteration. He presented with large, orange tonsils (Figure 1) and hepatosplenomegaly. There was no evidence of corneal opacities nor of other ocular abnormali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d6f00218c096fc9f19e5fec3c1ae54c
https://doi.org/10.1161/circulationaha.108.812164
https://doi.org/10.1161/circulationaha.108.812164
Autor:
Davide Pareyson, Roberta Ricciardi, M. Lombardi, Claudio Benvenuti, Angelo Sghirlanzoni, Giovanni Cei, Vittorio Cosi, Mariaflavia Nicora, Ferdinando Cornelio
Publikováno v:
Journal of neurology. 239(3)
The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61a39eb55d3e79d3a02d6dd96d712b4
https://pubmed.ncbi.nlm.nih.gov/1573422
https://pubmed.ncbi.nlm.nih.gov/1573422
Autor:
Alberto Muratorio, Ubaldo Bonuccelli, Giuseppe Rossi, Enio Martino, Angelo Nuti, Giovanni Cei, Lucia Grasso
Publikováno v:
Scopus-Elsevier
We studied the effectiveness of orally administered thyrotropin-releasing hormone (TRH) (40 mg/day) for 10 days against placebo in 11 patients with hereditary ataxias (HA). All patients completed the trial and none reported any noticeable side effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e3f1c3bce62c9604400e1f3d5c860e
http://www.scopus.com/inward/record.url?eid=2-s2.0-0024205641&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0024205641&partnerID=MN8TOARS
